JP2021534091A5 - - Google Patents

Info

Publication number
JP2021534091A5
JP2021534091A5 JP2021506297A JP2021506297A JP2021534091A5 JP 2021534091 A5 JP2021534091 A5 JP 2021534091A5 JP 2021506297 A JP2021506297 A JP 2021506297A JP 2021506297 A JP2021506297 A JP 2021506297A JP 2021534091 A5 JP2021534091 A5 JP 2021534091A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
carcinoma
cell
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021506297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534091A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/071024 external-priority patent/WO2020030591A1/en
Publication of JP2021534091A publication Critical patent/JP2021534091A/ja
Publication of JP2021534091A5 publication Critical patent/JP2021534091A5/ja
Pending legal-status Critical Current

Links

JP2021506297A 2018-08-05 2019-08-05 抗がん剤の有効性を改善する方法 Pending JP2021534091A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18187408 2018-08-05
EP18187408.2 2018-08-05
PCT/EP2019/071024 WO2020030591A1 (en) 2018-08-05 2019-08-05 Method for improving anticancer agent efficacy

Publications (2)

Publication Number Publication Date
JP2021534091A JP2021534091A (ja) 2021-12-09
JP2021534091A5 true JP2021534091A5 (enExample) 2022-06-27

Family

ID=63165228

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506297A Pending JP2021534091A (ja) 2018-08-05 2019-08-05 抗がん剤の有効性を改善する方法

Country Status (11)

Country Link
US (1) US20210299170A1 (enExample)
EP (1) EP3829637A1 (enExample)
JP (1) JP2021534091A (enExample)
KR (1) KR20210040997A (enExample)
CN (1) CN112689517A (enExample)
AU (1) AU2019317986A1 (enExample)
BR (1) BR112021002106A2 (enExample)
CA (1) CA3106429A1 (enExample)
IL (1) IL280608A (enExample)
MX (1) MX2021001394A (enExample)
WO (1) WO2020030591A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024508395A (ja) * 2021-02-10 2024-02-27 グレート ノベル セラピューティクス バイオテック アンド メディカルズ コーポレイション がんに対する免疫応答を刺激する又は免疫抑制を克服するための医薬組み合わせ及び方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020064471A (ko) * 2001-02-01 2002-08-09 황성하 소나무숯의 제조방법 및 그의 신규한 항암 치료제로서의용도
CN1657100B (zh) * 2004-02-19 2010-05-05 中国人民解放军军事医学科学院毒物药物研究所 选择性靶向胃癌和淋巴系统的纳米级制剂及其制备方法
US20080317666A1 (en) * 2005-02-09 2008-12-25 Elias Fattal Colonic Delivery of Active Agents
ES2429095T3 (es) 2005-05-18 2013-11-13 Da Volterra Aporte colónico de adsorbentes
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
KR101820374B1 (ko) * 2010-02-23 2018-01-19 다 볼떼라 장 내 흡착제의 경구 전달을 위한 제형
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
JP6456830B2 (ja) 2012-09-21 2019-01-23 フェリング ベスローテン フェンノートシャップ 医薬組成物
EP2876167A1 (en) * 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
BR112016023360B1 (pt) 2014-04-17 2023-03-07 Synthetic Biologics, Inc Beta-lactamase e seu uso
FR3027307B1 (fr) 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
EP3229802A1 (en) * 2014-12-09 2017-10-18 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
PE20180673A1 (es) * 2015-06-01 2018-04-19 Univ Chicago Tratamiento contra el cancer por manipulacion de la microflora comensal
WO2017003908A1 (en) * 2015-06-30 2017-01-05 The Trustees Of Columbia University In The City Of New York Talc-bound compositions and uses thereof

Similar Documents

Publication Publication Date Title
CN103282037B (zh) 抗肿瘤生物碱的联合治疗
Boyiadzis et al. Approved monoclonal antibodies for cancer therapy
US20160287717A1 (en) Core and Surface Modification of Mesoporous Silica Nanoparticles to Achieve Cell Specific Targeting In Vivo.
RU2019109211A (ru) Композиции, содержащие носитель-pd-l1-связывающий агент для лечения рака
US11034757B2 (en) Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
CN109196103A (zh) 自组装的3d rna笼形纳米粒
EP3735250A1 (en) Scale up synthesis of silicasome nanocarriers
JP2023533937A5 (enExample)
EP3851122A1 (en) Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
JP2021528496A5 (enExample)
JP2016532639A (ja) 薬物を負荷した二重特異性リガンド標的化ミニ細胞およびインターフェロン−γを用いた併用腫瘍治療
JP2022507025A5 (enExample)
JPWO2020111018A1 (ja) 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療
RU2010151602A (ru) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
TW202207904A (zh) 用於治療癌症及癌症抗藥性之脂質體調配物
JP2018535206A5 (enExample)
JP2022534724A5 (enExample)
JP2021534091A5 (enExample)
CN114469949A (zh) 用于治疗弥漫大b细胞淋巴瘤的喹啉衍生物
US11173173B2 (en) Methods for treating chemoresistant cancer-initiating cells
CN112121048A (zh) 用于联合治疗食管癌的喹啉类化合物
Praça et al. Current aspects of breast cancer therapy and diagnosis based on a nanocarrier approach
US10758526B2 (en) Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
RU2021105524A (ru) Способ повышения эффективности противоопухолевого средства
CA3231639A1 (en) Triple-agent therapy for cancer treatment